Avoid common mistakes on your manuscript.
Acute radiation dermatitis (RD) is the most common side effect of radiotherapy for breast cancer, affecting the majority of patients [1]. Ionizing radiation disrupts the self-renewing properties of the epidermis, thus impairing its barrier function and making patients more susceptible to infection. The clinical appearance is characterized by erythema, swelling, pruritus, discomfort, and dry or moist desquamation [2]. Severe cases with erosions and ulcerations might even require interruption or premature termination of radiation treatment, hampering tumour control outcomes. Following ongoing advancements in radiation treatment technique, dose fractionation, patient positioning, and de-escalation resulting from improved understanding of recurrence patterns, the latter has become rare; however, even mild symptoms are known to majorly impact quality of life and self-image of breast cancer patients [3]. Several trials have investigated patient-specific predictive factors associated with RD, identifying body mass index, breast volume, smoking habits, and diabetes mellitus [4,5,6]. The majority of these are non-modifiable risk factors, which do not allow any specific starting point for preventative or therapeutic approaches, which are clearly needed in this context [7].
Two recently published brief reports identified the skin microbiome as a new and potentially modifiable risk factor for RD in patients undergoing radiotherapy for breast cancer. In an initial report, Kost et al. showed that nasal Staphylococcus aureus colonization may be associated with RD severity [8]. Furthermore, Hülpüsch et al. demonstrated that in patients developing severe RD, an overgrowth of non-species-specific skin bacteria was observed before the onset of severe symptoms [9]. The exact interplay between the radiation-damaged skin barrier and the skin microbiome (both its absolute load as well as its composition) is not yet fully understood and might go beyond a mere increased susceptibility for local infections. Both trials, however, suggest the further investigation of the skin microbiome composition as a promising path towards a long-sought potential predictive biomarker. Specific cancer patient predispositions (e.g. immune status) are usually non-modifiable, yet these new insights might enable easily applicable personalized prevention strategies.
So far, two trials have investigated preventative strategies based on microbial decolonization. The follow-up trial by Kost et al. tested this rationale and investigated the use of a chlorhexidine body cleanser (applied once daily for five consecutive days prior to radiotherapy and then for five days every two weeks throughout treatment) to achieve bacterial decolonization [10]. This preventative regimen was associated with significantly reduced clinician-reported RD severity, along with the expected significantly lower rates of colonization with Staphylococcus aureus in comparison with the standard of care group. A single patient only experienced an adverse event (itching) related to the intervention. Another promising RD prevention strategy based on microbial decolonization is the topical application of non-invasive physical plasma (NIPP). This very well-tolerated partially ionized gas characterized by free electrons and generated out of ambient air has shown promising results in a phase 1 and 2 trial, with a significant positive impact on both patient- and clinician-reported outcomes in breast cancer patients [11, 12]. NIPP is already routinely applied for the treatment of chronic wounds such as diabetic foot ulcers, where a significantly improved wound healing was denoted across multiple phase 3 trials, partly owing to the significant reduction of the bacterial load compared to baseline assessments [13, 14]. Furthermore, NIPP induces the proliferation and migration of keratinocytes, fibroblasts, and endothelial cells, through the expression of wound healing and tissue regenerating gene signatures. Contrary to the above-mentioned chlorhexidine, NIPP has no known side effects, making it a very appealing prevention method. A randomized double-blind placebo-controlled phase 3 trial of NIPP in breast cancer patients undergoing adjuvant radiotherapy is currently ongoing and will unequivocally establish its role in RD prevention (NIPP-RD III; ARO-2024–07; DRKS00032560).
The impact of certain shifts in the composition of the skin microbiome following radiotherapy is also of interest. A reduced microbial diversity leads to an overrepresentation of certain taxa, the metabolic abilities of which have been shown to modify the RD risk (e.g. resulting in delayed recovery or higher tendency towards developing chronic RD) [9, 15, 16]. The impact of the above-mentioned preventative strategies on the microbial composition as well as new potential approaches is worthy of further investigation. Future trials will hopefully further elucidate the interplay between host and skin microbiome in the complex pathogenesis of RD and add to the emerging evidence of the skin microbiome as a modifiable risk factor for radiation dermatitis in breast cancer.
Data availability
No datasets were generated or analyzed during the current study.
References
Singh M, Alavi A, Wong R, Akita S (2016) Radiodermatitis: a review of our current understanding. Am J Clin Dermatol 17:277–292. https://doi.org/10.1007/s40257-016-0186-4
Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D et al (2015) Acute and short-term toxic effects of conventionally fractionated vs. hypofractionated whole-breast radiation: a randomized clinical trial. JAMA Oncol 1:931–41. https://doi.org/10.1001/jamaoncol.2015.2666
Rzepecki A, Birnbaum M, Ohri N, Daily J, Fox J, Bodner W et al (2022) Characterizing the effects of radiation dermatitis on quality of life: a prospective survey-based study. J Am Acad Dermatol 86:161–163. https://doi.org/10.1016/j.jaad.2019.03.011
Xie Y, Wang Q, Hu T, Chen R, Wang J, Chang H et al (2021) Risk factors related to acute radiation dermatitis in breast cancer patients after radiotherapy: a systematic review and meta-analysis. Front Oncol 11:738851
Böhner AMC, Koch D, Schmeel FC, Röhner F, Schoroth F, Sarria GR et al (2020) Objective evaluation of risk factors for radiation dermatitis in whole-breast irradiation using the spectrophotometric L*a*b* colour-space. Cancers (Basel) 12:9. https://doi.org/10.3390/cancers12092444
Behroozian T, Milton L, Li N, Zhang L, Lou J, Karam I et al (2021) Predictive factors associated with radiation dermatitis in breast cancer. Cancer Treat Res Commun 28:100403. https://doi.org/10.1016/j.ctarc.2021.100403
Behroozian T, Bonomo P, Patel P, Kanee L, Finkelstein S, van den Hurk C et al (2023) Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations. Lancet Oncol 24:e172–e185. https://doi.org/10.1016/S1470-2045(23)00067-0
Kost Y, Rzepecki AK, Deutsch A, Birnbaum MR, Ohri N, Hosgood HD et al (2023) Association of Staphylococcus aureus colonization with severity of acute radiation dermatitis in patients with breast or head and neck cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.0454
Hülpüsch C, Neumann AU, Reiger M, Fischer JC, de Tomassi A, Hammel G et al (2024) Association of skin microbiome dynamics with radiodermatitis in patients with breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.6533
Kost Y, Deutsch A, Mieczkowska K, Nazarian R, Muskat A, Hosgood HD et al (2023) Bacterial decolonization for prevention of radiation dermatitis: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.0444
Dejonckheere CS, Torres-Crigna A, Layer JP, Layer K, Wiegreffe S, Sarria GR et al (2022) Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: a first-in-human feasibility study. Pharmaceutics 14(9):1767. https://doi.org/10.3390/pharmaceutics14091767
Dejonckheere CS, Layer JP, Nour Y, Glasmacher A, Wiegreffe S, Fuhrmann A et al (2023) Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: results from an intrapatient-randomised double-blind placebo-controlled trial. Clin Transl Radiat Oncol 44:100699. https://doi.org/10.1016/j.ctro.2023.100699
Stratmann B, Costea T-C, Nolte C, Hiller J, Schmidt J, Reindel J et al (2020) Effect of cold atmospheric plasma therapy vs standard therapy placebo on wound healing in patients with diabetic foot ulcers: a randomized clinical trial. JAMA Netw Open 3:2010411. https://doi.org/10.1016/j.ctro.2023.100699
Mirpour S, Fathollah S, Mansouri P, Larijani B, Ghoranneviss M, Mohajeri Tehrani M et al (2020) Cold atmospheric plasma as an effective method to treat diabetic foot ulcers: a randomized clinical trial. Sci Rep 10:10440. https://doi.org/10.1038/s41598-020-67232-x
Ramadan M, Hetta HF, Saleh MM, Ali ME, Ahmed AA, Salah M (2021) Alterations in skin microbiome mediated by radiotherapy and their potential roles in the prognosis of radiotherapy-induced dermatitis: a pilot study. Sci Rep 11:5179. https://doi.org/10.1038/s41598-021-84529-7
Shi W, Zhang L, Yu X (2023) Skin microbiome composition is associated with radiation dermatitis in breast cancer patients undergoing radiation after reconstructive surgery: a prospective, longitudinal study. Int J Radiat Oncol Biol Phys 117:e207. https://doi.org/10.1016/j.ijrobp.2023.06.1091
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
CSD wrote the first draft of the manuscript. All other authors reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dejonckheere, C.S., Layer, J.P., Schmeel, L.C. et al. Identification of the skin microbiome as an emerging and modifiable risk factor for radiation dermatitis in breast cancer. Support Care Cancer 32, 538 (2024). https://doi.org/10.1007/s00520-024-08747-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-024-08747-1